Kevin C Conlon (Kevin Conlon)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Combination Therapy

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Rom S Leidner, Kevin C Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati V Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O'Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for immunotherapy of cancer 11 (10) (2023)
Kevin C Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William Douglas Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati V Gupta, Rom S Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer 9 (11) (2022)
Sigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R Bryant, Michael N Petrus, Liyanage P Perera, Jürgen R Müller, Joanna H Shih, Thomas A Waldmann, Kevin C Conlon
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. Journal for immunotherapy of cancer 9 (4) (2021)